Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Day One Biopharmaceuticals, Inc. large stockholder AI Day1 LLC and its affiliated reporting persons, including Len Blavatnik, have exited their position in the company. They tendered all shares into Servier Detroit Inc.’s cash tender offer at $21.50 per share, with pre-funded warrants converted into $21.4999 per warrant in cash. Following settlement on April 23, 2026, the group reports beneficial ownership of 0% of Day One’s common stock and confirms they ceased to be holders of more than five percent of the shares on that date.
Day One Biopharmaceuticals, Inc. insider entity AI Day1 LLC, a 10% owner, disposed of its entire position in connection with the company’s cash sale to Servier Detroit Inc. AI Day1 tendered 12,929,322 shares of Common Stock at $21.50 per share, all of which were accepted on April 23, 2026.
On the same date, each of AI Day1’s 827,586 pre-funded warrants to purchase Common Stock was converted into the right to receive $21.4999 in cash per warrant, leaving no remaining share or warrant holdings. The filing notes that these securities were held directly by AI Day1 and may be deemed beneficially owned by related Access Industries entities and Len Blavatnik, who each disclaim beneficial ownership beyond their pecuniary interest.
Day One Biopharmaceuticals, Inc. filed a Form 4 showing that Chief Executive Officer Jeremy Bender and related entities disposed of their equity in connection with the closing of the company’s cash merger with Servier. On April 23, 2026, each outstanding share of common stock was purchased or converted into the right to receive $21.50 per share in cash under the merger agreement. Various family trusts, including The Jeremy Bender 2023 Grantor Retained Annuity Trust and several Melissa Bender Grantor Retained Annuity Trusts, disposed of their Day One common shares to the issuer as part of the transaction. Bender’s directly held common stock, RSUs and stock options were also canceled and converted into cash based on the Merger Consideration, with options paid the difference between $21.50 and their exercise price. Following these issuer dispositions, the Form 4 shows zero shares and zero derivative awards remaining for the reported positions.
Day One Biopharmaceuticals executive Michael Vasconcelles disposed of all company equity holdings in connection with the closing of a cash merger. The filing shows that, upon the merger with Servier, each share of Common Stock was purchased or converted into the right to receive $21.50 in cash per share under the merger agreement.
Vasconcelles returned 4,397 Common shares to the issuer and all outstanding equity awards were canceled for cash. This included 106,875 and 226,000 Restricted Stock Units, and stock options for 171,000 and 346,000 shares with exercise prices of $11.16 and $6.64, respectively. Following these dispositions, his reported holdings in these securities are zero.
Day One Biopharmaceuticals’ COO and CFO, Charles N. York II, reported the cancellation of his equity due to the company’s merger with Servier. On April 23, 2026, each share of Day One common stock was cashed out at $21.50 per share under the merger terms.
York disposed of 312,025 shares of common stock in an issuer disposition, leaving him with zero reported common shares. His unvested stock options and restricted stock units first became fully vested and were then canceled at the merger’s effective time in exchange for cash equal to the merger consideration (or the merger price minus the option exercise price), less applicable taxes.
The filing shows multiple cancellations of RSUs and stock options covering hundreds of thousands of underlying shares, with all related derivative positions reported as 0 remaining after the merger.
Day One Biopharmaceuticals’ General Counsel & Secretary Adam Dubow disposed of all reported equity holdings in connection with the company’s cash merger. On the April 23, 2026 closing of the merger with Servier, each share of common stock was purchased or converted into the right to receive $21.50 in cash per share, subject to taxes.
The filing shows 72,694 shares of common stock and multiple grants of restricted stock units and stock options reported as dispositions to the issuer. Footnotes state that unvested stock options and RSUs became fully vested immediately before the merger, then were canceled for cash based on the $21.50 merger consideration (less the applicable exercise price for options). After these transactions, the form reports zero shares and zero derivatives remaining for the reporting person.
Day One Biopharmaceuticals director Natalie C. Holles reported the cash-out of all remaining equity awards in connection with the Servier acquisition. On April 23, 2026, her 57,310 shares of common stock, 15,000 restricted stock units, and multiple stock option grants were disposed of to the issuer at the merger closing.
Under the merger completed at an Offer Price of $21.50 per share, each common share was purchased or converted into the right to receive cash, and each stock option and RSU was canceled for a cash payment based on the merger consideration, less any required taxes. Following these transactions, the Form 4 shows no remaining common stock or derivative holdings for Holles.
Day One Biopharmaceuticals director Saira Ramasastry disposed of all reported equity interests in connection with the company’s cash merger with Servier. The filing shows 40,485 shares of Common Stock, 15,000 restricted stock units and multiple stock option grants were surrendered to the issuer on April 23, 2026.
Under the merger, each Day One share was purchased or converted into the right to receive $21.50 in cash, and each option or RSU was canceled for a cash payment based on this price, less any applicable exercise price and taxes. Following these transactions, the Form 4 lists no remaining shares or options for the reporting person.
Day One Biopharmaceuticals director John A. Josey disposed of his equity in connection with the company’s cash merger with Servier. Following the April 23, 2026 closing, his 72,292 shares of common stock were converted into cash at $21.50 per share under the merger terms.
His 15,000 restricted stock units and multiple fully vested stock option grants, covering tens of thousands of shares with exercise prices including $7.01 and $8.99, were canceled and converted into cash based on the merger consideration. After these issuer dispositions, the Form 4 shows no remaining common stock or derivative holdings.